search
Back to results

Genital Nerves Stimulation for Treatment for Erectile Dysfunction (GNS)

Primary Purpose

Erectile Dysfunction

Status
Not yet recruiting
Phase
Not Applicable
Locations
Switzerland
Study Type
Interventional
Intervention
Genital Nerves Stimulation
Sponsored by
Prof. Dr. med. Marc Possover
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Erectile Dysfunction focused on measuring erectile dysfunction, Genital Nerves Stimulation

Eligibility Criteria

19 Years - 90 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients presenting characteristic symptoms of refractory ED

Exclusion Criteria:

  • Patients<18y and >90y

    • Patients who have an implanted pacemaker
    • Vulnerable patients with co-morbid conditions should be excluded from this study. These co-morbid conditions include all pathologies of the cardiovascular system (Angina Pectoris, Infarct, Thrombose, Embolie, Hypertonia), pulmonary system (asthma, COPD, chr. Bronchitis), intestinal system (morbus Crohn, diverticulitis..) and any malignant disease. These co-morbid conditions also include neurologic diseases (i.e., stroke, multiple sclerosis, spinal cord injury), sacral dermal pathological conditions, congenital or other anatomical sacral anomalies (e.g. spina bifida, sacral agenesis, trauma sequelae), mobility deficits, medically complicated/uncontrolled diabetes, fecal motility disorders (fecal incontinence/constipation), chronic pelvic pain, history of recurrent urinary tract infections (UTIs), gross hematuria, prior pelvic/vaginal surgeries (incontinence/prolapse surgeries), pelvic cancer (bladder, colon, cervix, uterus, prostate), deeply infiltrating endometriosis of the pelvic plexus, sacral plexus or of the bladder, Reiter´s syndrome, and pelvic radiation.
    • Patients suffering from other CNS disorders (mental disorders, severe psychological problems, cerebrovascular accident less than 6 months ago).
    • Allergies again skin adhesive electrodes
    • Patients with genital lesions/surgeries, pudendal nerve lesion/surgery or genital surgeries, vascular disease or neurological disorders were excluded. Due to the risk of iatrogenic lesions of the erectile nerves, patients suffering from ED secondary to radical prostatectomy are not prime candidates for such a study, however due to the incidence of this etiology and the important impact in the general male population, we decided to include these patients in our study.

Sites / Locations

  • Possover

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Arm A - 20Hz Stimulation

Arm B - 60Hz Stimulation

Arm Description

Transcutaneous stimulation of the genital nerves at 20Hz

Transcutaneous stimulation of the genital nerves at 60Hz

Outcomes

Primary Outcome Measures

Transcutaneous electrical stimulation of the Genital Nerves for treatment ED
Examining the efficacy of transcutaneous genital nerve stimulation (TENS) in the treatment of ED utilizing the International Index of Erectile Function-15 score: A. Erectile function (Q1,2,3,4,5,15): Max score 30 B. Orgasmic function (Q9,19): Max score 10 C: Sexual desire (Q11,12): Max score 10 D: Intercourse satisfaction (Q6,7,8): Max score 15 E: Overall satisfaction (Q13,14): Max Score 10 IEEFscores <14 out of 39 in domain A (erectile function) may be considered for therapy and referred for specialist investigation.

Secondary Outcome Measures

Quality of erection by using two different frequency of stimulation
The quality of erection by using the Erectile Function-15 score will be compared between two different frequency of stimulation, 20 and 60Hz with following scores: A. Erectile function (Q1,2,3,4,5,15): Max score 30 B. Orgasmic function (Q9,19): Max score 10 C: Sexual desire (Q11,12): Max score 10 D: Intercourse satisfaction (Q6,7,8): Max score 15 E: Overall satisfaction (Q13,14): Max Score 10 IEEFscores <14 out of 39 in domain A (erectile function) may be considered for therapy and referred for specialist investigation.

Full Information

First Posted
December 31, 2021
Last Updated
May 2, 2023
Sponsor
Prof. Dr. med. Marc Possover
search

1. Study Identification

Unique Protocol Identification Number
NCT05231083
Brief Title
Genital Nerves Stimulation for Treatment for Erectile Dysfunction
Acronym
GNS
Official Title
Transcutaneous Electrical Stimulation of the Genital Nerves (GN) to Improve Erection Dysfunction (ED) in Men: a Pilot Study
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
February 1, 2025 (Anticipated)
Primary Completion Date
August 1, 2025 (Anticipated)
Study Completion Date
September 1, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Prof. Dr. med. Marc Possover

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Objectives: To perform pilot study using unilateral transcutaneous electrical stimulation (TENS) on thegenital nerves (dorsal nerve penis and cavernous nerves) for improving of the intracorpereal pressure and full penil erection in men after exclusion neurogenic, endrogenic and earteriogenic disorders. The investigators hypothesize that this therapy will be effective at improving erectile dysfunction (ED). Material and methods: The study will comprised 20 patients with ED randomized in two groups. Two adhesive skin electrodes are placed, one at the root of the penis and near the pubic symphysis as a cathode, and a second 2-3cm lateral to the penis. Stimulation is delivered for 30 min at the maximal tolerable stimulation amplitude at 210μs pulse width and in one group with a pulse rate at 20Hz, the second group at 60Hz. The penile tumescence and rigidity observed during stimulation are recorded in both groups of patients. Erection Harness Score (EHS) and Quality of Erection Questionnaire (QEQ) are assessed at baseline, immediately after stimulation and 2 weeks after stimulation.
Detailed Description
The study is a randomized prospective unblended study. 20 male patients with ED participated to the study. Vulnerable patients, patients with a pacemaker, patients with genital lesions, previous pudendal nerve or genital surgeries, vascular disease or neurological disorders are excluded. Due to the risk of iatrogenic lesions of the erectile nerves, patients suffering from ED secondary to radical prostatectomy are not prime candidates for such a study, however due to the incidence of this etiology and the important impact in the general male population, the investigators decided to include these patients in participants study. The assessment at baseline consistes of a medical history, a neuropelveological workup of the pelvic somatic nerves, pudendal ultrasonography with doppler. Stimulation is performed using a battery powered handled stimulator (N602-1C TENS Elektrostimulator - CH). Monophasic square constant current pulse with a pulse duration of 210 μs. The patients are randomized into two separate groups, a group A with fixed stimulation at 20Hz, a group B with fixed stimulation at 60Hz. Because both genital nerves are located just few millimeters below the skin, stimulation can be achieved using two adhesive skin surface electrodes (diameter 32mm, PALS Platinum, Axelgaard, Lystrup, Denmark), one placed at the root of the penis and in vicinity of the symphysis pubis as a cathode, and a second 2-3cm lateral to the penis. Precautions are taken to ensure good contact between skin and the electrodes, including removal of hairs. Furthermore, the patients are instructed to place the electrodes correctly and to clean the skin before application of the electrodes. The patients are encouraged to set the amplitude as high as tolerable each time when stimulating at home. Because the different genital nerves may react to different frequency of stimulation , stimulation is delivered for 30 min at the maximal tolerable stimulation amplitude at 210μs pulse width with a pulse rate at 20Hz in patients group A, and at 60Hz in patients group B. The first transcutaneous stimulation is performed in the presence of MP: The penile tumescence and rigidity observed during stimulation are recorded in both groups of patients. Then stimulation is performed at home at least twice daily for 15 min in each session for a period of 2 weeks. The patients recorde the stimulation amplitude after each session. Erection Harness Score (EHS) and Quality of Erection Questionnaire (QEQ) are assessed for 2 weeks before stimulation, during the 2 weeks of stimulation, and for 2 weeks after the final stimulation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Erectile Dysfunction
Keywords
erectile dysfunction, Genital Nerves Stimulation

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Monocebtric randomized unblinded pilote study
Masking
Investigator
Allocation
Randomized
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Arm A - 20Hz Stimulation
Arm Type
Experimental
Arm Description
Transcutaneous stimulation of the genital nerves at 20Hz
Arm Title
Arm B - 60Hz Stimulation
Arm Type
Experimental
Arm Description
Transcutaneous stimulation of the genital nerves at 60Hz
Intervention Type
Device
Intervention Name(s)
Genital Nerves Stimulation
Intervention Description
Transcutaneous electrical stimulation of the genital nerves using a TENS device and skin adhesive surface electrodes
Primary Outcome Measure Information:
Title
Transcutaneous electrical stimulation of the Genital Nerves for treatment ED
Description
Examining the efficacy of transcutaneous genital nerve stimulation (TENS) in the treatment of ED utilizing the International Index of Erectile Function-15 score: A. Erectile function (Q1,2,3,4,5,15): Max score 30 B. Orgasmic function (Q9,19): Max score 10 C: Sexual desire (Q11,12): Max score 10 D: Intercourse satisfaction (Q6,7,8): Max score 15 E: Overall satisfaction (Q13,14): Max Score 10 IEEFscores <14 out of 39 in domain A (erectile function) may be considered for therapy and referred for specialist investigation.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Quality of erection by using two different frequency of stimulation
Description
The quality of erection by using the Erectile Function-15 score will be compared between two different frequency of stimulation, 20 and 60Hz with following scores: A. Erectile function (Q1,2,3,4,5,15): Max score 30 B. Orgasmic function (Q9,19): Max score 10 C: Sexual desire (Q11,12): Max score 10 D: Intercourse satisfaction (Q6,7,8): Max score 15 E: Overall satisfaction (Q13,14): Max Score 10 IEEFscores <14 out of 39 in domain A (erectile function) may be considered for therapy and referred for specialist investigation.
Time Frame
60 months

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
male
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients presenting characteristic symptoms of refractory ED Exclusion Criteria: Patients<18y and >90y Patients who have an implanted pacemaker Vulnerable patients with co-morbid conditions should be excluded from this study. These co-morbid conditions include all pathologies of the cardiovascular system (Angina Pectoris, Infarct, Thrombose, Embolie, Hypertonia), pulmonary system (asthma, COPD, chr. Bronchitis), intestinal system (morbus Crohn, diverticulitis..) and any malignant disease. These co-morbid conditions also include neurologic diseases (i.e., stroke, multiple sclerosis, spinal cord injury), sacral dermal pathological conditions, congenital or other anatomical sacral anomalies (e.g. spina bifida, sacral agenesis, trauma sequelae), mobility deficits, medically complicated/uncontrolled diabetes, fecal motility disorders (fecal incontinence/constipation), chronic pelvic pain, history of recurrent urinary tract infections (UTIs), gross hematuria, prior pelvic/vaginal surgeries (incontinence/prolapse surgeries), pelvic cancer (bladder, colon, cervix, uterus, prostate), deeply infiltrating endometriosis of the pelvic plexus, sacral plexus or of the bladder, Reiter´s syndrome, and pelvic radiation. Patients suffering from other CNS disorders (mental disorders, severe psychological problems, cerebrovascular accident less than 6 months ago). Allergies again skin adhesive electrodes Patients with genital lesions/surgeries, pudendal nerve lesion/surgery or genital surgeries, vascular disease or neurological disorders were excluded. Due to the risk of iatrogenic lesions of the erectile nerves, patients suffering from ED secondary to radical prostatectomy are not prime candidates for such a study, however due to the incidence of this etiology and the important impact in the general male population, we decided to include these patients in our study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marc Possover, PhD
Phone
+41797507995
Email
m.possover@possover.com
First Name & Middle Initial & Last Name or Official Title & Degree
Marc Possover
Phone
+415203600
Email
mail@possover.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marc Possover
Organizational Affiliation
Possover International Medical Center AG
Official's Role
Principal Investigator
Facility Information:
Facility Name
Possover
City
Zürich
ZIP/Postal Code
8008
Country
Switzerland

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Genital Nerves Stimulation for Treatment for Erectile Dysfunction

We'll reach out to this number within 24 hrs